Clinical Trial Results:
A phase III open-label randomised study to evaluate the immunogenicity and safety of the concomitant administration of a new Hexavalent DTaP-IPV-HB-Hib combined vaccine (Hexavalent vaccine) given at 2, 3, and 4 months of age with a meningococcal serogroup C conjugate (MenC) vaccine given at 2 and 4 months of age.
Short title:
Concomitant administration of a new hexavalent vaccine (Hexavalent vaccine) with a meningococcal serogroup C conjugate vaccine in healthy infants during primary series immunisation followed by booster vaccination
Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.
Summary
|
|
EudraCT number |
2012-005547-24 |
Trial protocol |
FI |
Global end of trial date |
11 Feb 2015
|
Results information
|
|
Results version number |
v1 |
This version publication date |
13 Apr 2016
|
First version publication date |
18 Mar 2015
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
HXM01C
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01839175 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur MSD SNC
|
||
Sponsor organisation address |
162 avenue Jean Jaurès - CS 50712, Lyon Cedex 07, France, 69367
|
||
Public contact |
Clinical Trials Disclosure, Sanofi Pasteur MSD S.N.C., ClinicalTrialsDisclosure@spmsd.com
|
||
Scientific contact |
Clinical Trials Disclosure, Sanofi Pasteur MSD S.N.C., ClinicalTrialsDisclosure@spmsd.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
29 Jul 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
29 Jul 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
11 Feb 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
PRIMARY SERIES (Period 2):
- To demonstrate that the concomitant administration of the hexavalent vaccine given at 2, 3 and 4 months of age with a meningococcal serogroup C conjugate (MenC) vaccine given at 2 and 4 months of age is non inferior to the administration of the hexavalent vaccine without a MenC vaccine concomitantly in term of seroprotection rate for hepatitis B one month after the third dose of the hexavalent vaccine.
- To demonstrate that the concomitant administration of a MenC vaccine given at 2 and 4 months of age with the hexavalent vaccine given at 2, 3 and 4 months of age induces an acceptable response for MenC in term of seroprotection rate (SPR) one month after the second dose of MenC.
BOOSTER:
To describe the immunogenicity of a booster dose of the hexavalent vaccine and of a meningococcal group ACWY conjugate vaccine either co-administered at 12 months of age or given separately.
|
||
Protection of trial subjects |
Subjects in the study received three injections during primary series (period 2) and one injection during the booster part of a single dose of the study vaccine DTaP-IPV-HB-Hib supplied in a prefilled 0.5 mL syringe that was administered by qualified study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After each vaccination, subjects were also kept under observation for 30 minutes to ensure their safety. Appropriate equipment was also available on site in case of any immediate allergic reactions.
|
||
Background therapy |
Not Applicable | ||
Evidence for comparator |
The control group complies with the recommended vaccination schedules for all vaccines (i.e. Study vaccine and routine vaccines) as per their respective Summaries of Product Characteristics (SmPCs). | ||
Actual start date of recruitment |
29 Apr 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Finland: 350
|
||
Worldwide total number of subjects |
350
|
||
EEA total number of subjects |
350
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
350
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||
Recruitment details |
Study subjects were enrolled from 29 April 2013 to 09 August 2013 in 11 clinical centers in Finland. | |||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||
Screening details |
A total of 354 subjects were screened out of which 350 subjects who met all the inclusion but none of the exclusion criteria were randomised and vaccinated. | |||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||
Period 1 title |
Randomisation
|
|||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||||||||
Blinding implementation details |
This was an open-label study as the number of vaccines administered in each group was different at several visits. Blinding would have required a placebo injection which was not deemed necessary since the primary endpoints were based on immunological criteria. Serology tests for the hexavalent vaccine antigens were performed by laboratory staff blinded to subject group.
|
|||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Hexavalent vaccine co-administered with MenC vaccine | |||||||||||||||||||||||||||
Arm description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age co-administered with 2 doses of MenC vaccine with one dose each at 2, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Hexyon (Hexavalent vaccine)
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
DTaP-IPV-HB-Hib
|
|||||||||||||||||||||||||||
Other name |
Hexacima / Hexaxim
|
|||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular route, one dose at 2, 3, and 4 months of age.
|
|||||||||||||||||||||||||||
Investigational medicinal product name |
NeisVac-C
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
MenC vaccine
|
|||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular route, one dose at 2, and 4 months of age.
|
|||||||||||||||||||||||||||
Arm title
|
Hexavalent vaccine without MenC vaccine | |||||||||||||||||||||||||||
Arm description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | |||||||||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||||||||
Investigational medicinal product name |
Hexyon (Hexavalent vaccine)
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
DTaP-IPV-HB-Hib
|
|||||||||||||||||||||||||||
Other name |
Hexacima / Hexaxim
|
|||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular route, one dose at 2, 3, and 4 months of age.
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Period 2
|
||||||||||||||||||||||||||||
Period 2 title |
Primary Series
|
|||||||||||||||||||||||||||
Is this the baseline period? |
No | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||||||||
Blinding implementation details |
This was an open-label study as the number of vaccines administered in each group was different at several visits. Blinding would have required a placebo injection which was not deemed necessary since the primary endpoints were based on immunological criteria. Serology tests for the hexavalent vaccine antigens were performed by laboratory staff blinded to subject group.
|
|||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Hexavalent vaccine co-administered with MenC vaccine | |||||||||||||||||||||||||||
Arm description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age co-administered with 2 doses of MenC vaccine with one dose each at 2, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Hexyon (Hexavalent vaccine)
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
DTaP-IPV-HB-Hib
|
|||||||||||||||||||||||||||
Other name |
Hexacima / Hexaxim
|
|||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular route, one dose at 2, 3, and 4 months of age.
|
|||||||||||||||||||||||||||
Investigational medicinal product name |
NeisVac-C
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
MenC vaccine
|
|||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular route, one dose at 2, and 4 months of age.
|
|||||||||||||||||||||||||||
Arm title
|
Hexavalent vaccine without MenC vaccine | |||||||||||||||||||||||||||
Arm description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | |||||||||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||||||||
Investigational medicinal product name |
Hexyon (Hexavalent vaccine)
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
DTaP-IPV-HB-Hib
|
|||||||||||||||||||||||||||
Other name |
Hexacima / Hexaxim
|
|||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular route, one dose at 2, 3, and 4 months of age.
|
|||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Hexavalent vaccine co-administered with MenC vaccine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age co-administered with 2 doses of MenC vaccine with one dose each at 2, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Hexavalent vaccine without MenC vaccine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Hexavalent vaccine co-administered with MenC vaccine
|
||
Reporting group description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age co-administered with 2 doses of MenC vaccine with one dose each at 2, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | ||
Reporting group title |
Hexavalent vaccine without MenC vaccine
|
||
Reporting group description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | ||
Reporting group title |
Hexavalent vaccine co-administered with MenC vaccine
|
||
Reporting group description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age co-administered with 2 doses of MenC vaccine with one dose each at 2, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | ||
Reporting group title |
Hexavalent vaccine without MenC vaccine
|
||
Reporting group description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. |
|
||||||||||||||||
End point title |
Seroprotection against Hepatitis B one month after vaccination with either Hexavalent vaccine co-administered with MenC vaccine or Hexavalent vaccine without MenC vaccine | |||||||||||||||
End point description |
Percentage of subjects with an anti-Hepatitis B surface antigen (Hep B) concentration ≥10 mIU/mL (measured by hepatitis B enhanced Chemiluminescence assay)
Analysis was done on the per protocol set.
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
One month post-dose 3 of Hexavalent vaccine.
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
non-inferiority of the immune response | |||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of the immune response of the concomitant administration of the Hexavalent vaccine co-administered with MenC vaccine as compared to the Hexavalent vaccine without Men C vaccine one month after the third dose.
|
|||||||||||||||
Comparison groups |
Hexavalent vaccine co-administered with MenC vaccine v Hexavalent vaccine without MenC vaccine
|
|||||||||||||||
Number of subjects included in analysis |
315
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
non-inferiority [1] | |||||||||||||||
Method |
Wilson score Method without cc | |||||||||||||||
Parameter type |
Difference in percentages of subjects | |||||||||||||||
Point estimate |
1.37
|
|||||||||||||||
Confidence interval |
||||||||||||||||
level |
95% | |||||||||||||||
sides |
2-sided
|
|||||||||||||||
lower limit |
-2.92 | |||||||||||||||
upper limit |
5.95 | |||||||||||||||
Notes [1] - The immune response of Hexavalent vaccine co-administered with MenC vaccine was considered as non-inferior to Hexavalent vaccine without MenC vaccine if the lower bound of the two-sided 95.0% Confidence Intervals (CI) of the difference in the percentages of subjects with anti-Hep B ≥10 mIU/mL measured one month after the third dose is greater than -10%. CI was based on the Wilson score method without continuity correction (cc). |
|
|||||||||||
End point title |
Seroprotection for MenC one month after vaccination with two doses of MenC [2] | ||||||||||
End point description |
Percentages of subjects with an anti-MenC titre ≥8 (1/dilution (dil)) (measured by Serum Bactericidal Antibody assay with rabbit complement) one month after two doses of MenC vaccine.
Analysis was done on the per protocol set.
The immune response to MenC vaccine was considered as acceptable if the lower bound of the two-sided 95.0% CI of the percentage of subjects with anti-MenC ≥8 (1/dil) one month after the second dose is greater than 90%
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
One month post-dose 2 of MenC vaccine.
|
||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The immune response to MenC vaccine was considered as acceptable if the lower bound of the two-sided 95.0% CI of the percentage of subjects with anti-MenC ≥8 (1/dil) one month after the second dose is greater than 90%. No comparison between arms was planned. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Response rates for all Hexavalent vaccine antigens one month after 3 doses of Hexavalent vaccine co-administered with MenC vaccine or 3 doses of Hexavalent vaccine without MenC vaccine | |||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Percentages of subjects with an anti-Hep B concentration ≥10 mIU/mL (measured by Hep B enhanced Chemiluminescence assay), with an anti-PRP concentration ≥0.15ug/mL for Hib by Farr type radioimmunoassay, with an anti-D concentration ≥0.01 IU/mL and ≥0.1 IU/mL for diphtheria by Micrometabolic Inhibition Test (MIT), with an anti-T concentration ≥0.01 IU/mL and ≥0.1 IU/mL for tetanus by enzyme linked immunosorbent assay (ELISA), with an anti-IPV titre ≥8 (1/dil) for poliovirus types 1, 2, and 3 by MIT, with an anti-PT vaccine response (VR), with an anti-FHA VR, with 4-fold increase for PT and FHA by ELISA (EU/mL).
Pertussis vaccine response (VR) is defined as:
- If pre-vaccination antibody concentration was <4*LLOQ, then the post-vaccination antibody concentration was to be ≥4*LLOQ,
- If pre-vaccination antibody concentration was ≥4*LLOQ, then the post-vaccination antibody concentration was to be ≥pre-immunisation levels
Analysis was done on the per protocol set
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
One month post-dose 3 of Hexavalent vaccine.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Response rates for MenC one month after vaccination with one dose or two doses of MenC Vaccine. | ||||||||||||||||
End point description |
Percentages of subjects with an anti-MenC titre ≥8 (1/dilution (dil)) or with an anti-MenC titre ≥128 (1/dil) (measured by Serum Bactericidal Antibody assay with rabbit complement) one month after one dose or one month after two doses of MenC vaccine.
Analysis was done on the per protocol set.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
One month post-dose 1 or post-dose 2 of MenC vaccine.
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titers or Concentrations of Antibodies one month after 3 doses of Hexavalent vaccine co-administered with MenC vaccine or 3 doses of Hexavalent vaccine without MenC vaccine | |||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers or concentrations were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection (mIU/mL), for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay (ug/mL), for diphtheria (D) by Micrometabolic Inhibition Test (IU/mL), for tetanus by enzyme linked immunosorbent assay (IU/mL), for poliovirus (IPV) types 1, 2, and 3 by Micrometabolic Inhibition Test (1/dil), for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA in EU/mL)).
Analysis was done on the per protocol set.
|
|||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||
End point timeframe |
One month post-dose 3 of Hexavalent vaccine.
|
|||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Geometric Mean Titers of Antibodies one month after 1 dose or 2 doses of MenC vaccine co-administered with Hexavalent vaccine | ||||||||||||
End point description |
Antibody titers were measured by Serum Bactericidal Antibody assay with rabbit complement (1/dil) one month after one dose or two doses of MenC vaccine
Analysis was done on the per protocol set.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
One month post-dose 1 or post-dose 2 of MenC vaccine.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects Reporting Solicited Injection Site or Systemic Reactions After Hexavalent vaccine co-administered with MenC vaccine or Hexavalent vaccine without MenC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Solicited Injection Site Reactions: Erythema, Pain, and Swelling; Solicited Systemic Reactions: Crying, Decreased appetite, Irritability, Pyrexia, Somnolence, and Vomiting within 7 days after any hexavalent vaccine injection with or without MenC vaccine. Analysis was done on the safety analysis set, i.e. all subjects who received at least one dose of the hexavalent vaccine and had any safety follow-up data.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 up to 7 days following any dose.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Unsolicited adverse events were collected from Day 0 up to 30 days after each vaccination. Serious adverse events were collected from the first vaccination and up to the last visit.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Hexavalent vaccine co-administered with MenC vaccine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age co-administered with 2 doses of MenC vaccine with one dose each at 2, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Hexavalent without MenC
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received 3 doses of hexavalent vaccine with one dose each at 2, 3, and 4 months of age. Subjects received also routine vaccination: RotaTeq at 2, 3, and 4 months of age and Prevenar 13 at 2, and 4 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
12 Nov 2013 |
Amendment 1 to Protocol (leading to Version 2.0) was produced to provide details regarding the booster vaccination at 12 to 13 months of age with hexavalent vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine and meningococcal C containing vaccine. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |